Double-blind placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy

The Journal of Allergy and Clinical Immunology

Volumn 82, Issue 3 PART 1, 1988, Pages 439-446

  Bousquet, J ^a,b   Maasch, H ^a,b   Martinot, B ^a,b   Hejjaoui, A ^a,b   Wahl, R ^a,b   Michel, F B ^a,b  

^a Reinbeck ^*

^b Reinbeck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G;

ADULT; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; SKIN TEST;

ADULT; ALLERGENS; DOUBLE-BLIND METHOD; HAY FEVER; HUMAN; IMMUNOGLOBULIN G; IMMUNOTHERAPY; NASAL PROVOCATION TESTS; POACEAE; POLLEN; SKIN TESTS; TIME FACTORS;

EID: 0023814205     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-6749(88)90017-6     Document Type: Article

References (42)

1. Immunotherapy
2. Immunotherapy
3. Clinical and immunologic aspects of allergenspecific immunotherapy in patients with seasonal allergic rhinitis and/or allergic asthma
4. Immunotherapy in hay fever with two major allegens 19 25 and partially purified extract of timothy grass pollen A controlled double-blind study In vivo variables season I
5. Comparison of rush immunotherapy with a standardized grass-pollen extract and classical immunotherapy with a pyridine extracted alum adjuved extract
6. Comparison of two dosages of ragweed extract in the treatment of pollenosis
7. Immunotherapy of hay fever with ragweed antigen E: comparison with whole pollen extract and placebo
8. Clinical studies of a purified timothy-pollen extract: desensitization therapy with a purified timothy-pollen preparation compared to a crude timothy-pollen extract. I. Results of tests in vivo
9. Hyposensitization in allergic seasonal rhinitis as evaluated by rhinomanometry
10. Immunotherapy for grass pollenosis with Allpyral allergen extracts improved results by objective control of treatment requirement
11. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy
12. Hyposensitization comparing a purified (refined) allergen preparation and a crude aqueous extract from timothy pollen
13. Hyposensitization in grass-pollen hay fever: a double-blind trial of alum-precipitated pollen extract and depot emulsion pollen extract: compared with placebo injections
14. Hyposensitization in childhood hay fever, a comparison of refined and whole timothy extracts
15. Mediator release after nasal spray airway challenge with allergen
16. Nasal challenge with pollen grains, skin tests, specific IgE in patients with grass-pollen allergy
17. Immunotherapy with grass pollen major allergens immunological results from a prospective 3-year double-blind study
18. IgE, IgG, and IgA antibodies in serum and nasal secretion during parenteral hyposensitization
19. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy
20. Immunotherapy in hay fever with two major allergens 19 25 and partially purified extracts of timothy pollen A controlled double-blind study In vitro variables season 1
21. Clinical studies of a purified timothy-pollen extract desensuization therapy with a purified timothy-pollen preparation compared to a crude timothy-pollen extract II Results of the tests in vitro and their relation to symptoms and tests in vivo
22. Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy
23. Depressed lymphocyte responses after hyposensitization
24. Blood lymphocyte proliferation response to pollen extract as a monitor of immunotherapy
25. Lymphocyte response to grass pollen antigens: a correlation with radioallergosorbent test and effect of immunotherapy
26. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps
27. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever
28. Double-blind placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen
29. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever
30. Double-blind placebo-controlled immunotherapy with high molecular weight formalinized ailergoid in grasspollen allergy
31. Skin testing
32. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment
33. Shelf-life of a pollen and a mite standardized extract
34. Inhalation challenge with ragweed pollen in ragweed-sensitive asthmatics
35. Methods for assessing nasal reactivity
36. Correlation between symptoms and release of mediators in secretions during nasal challenge with pollen grains
37. Measurement of “blocking antibodies” to pollen antigens by radiolabelled protein A from Staphylococcus aureus
38. Radioimmunosorbent assay for allergens
39. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed
40. 4 in allergic patients
41. Heterogenecity of metachromatic cells in human nose: significance of mucosal mast cells
42. Heterogeneity of mast cells